ReviewFrontiers in medicine2025
Recent progress in the clinicopathological characteristics of alveolar soft part sarcoma.
Review in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alveolar soft part sarcoma (ASPS) is a rare malignant soft tissue neoplasm characterized by distinctive histological features, indolent growth patterns and a propensity for metastasis. Recent advancements in molecular pathology and targeted therapies have significantly enhanced our understanding of its clinical and pathological characteristics. This paper systematically reviews the epidemiological profile, histopathological diagnostic criteria, molecular genetic mechanisms (notably the ASPSCR1-TFE3 gene fusion), immunophenotypic features, and differential diagnosis of ASPS. By integrating insights from multi-omics technologies, we explore the potential of personalized diagnostic and therapeutic strategies to improve disease comprehension and refine clinicopathological diagnostic standards, thereby guiding clinical management and enhancing patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.